Clinical Trial Update: Study to Investigate the Safety and Efficacy of K-321 in Patients With Fuchs Endothelial Corneal Dystrophy (FECD) Following Descemetorhexis [Phase 2]

View source ↗

Summary

Phase 2 study of K-321 for Fuchs' Endothelial Corneal Dystrophy following Descemetorhexis has completed, with results posted on 2024-11-05.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fuchs Endothelial Corneal Dystrophy

Drugs mentioned

• K-321

Snippet

Sponsor: Kowa Research Institute, Inc. | Conditions: Fuchs' Endothelial Corneal Dystrophy | Phase 2 | Status: COMPLETED | Results posted: 2024-11-05